Sažetak
Uvod/Cilj. Hipertenzija je jedan od vodećih uzroka kardiovaskularnog morbiditeta i mortaliteta u Srbiji, te više od polovine troškova za lekove na teret osiguranja odlazi na antihipertenzivne lekove. Cilj ove studije bio je analiza strukture upotrebe antihipertenzivnih lekova kod hipertenzivnih vanbolničkih pacijenata u Novom Sadu, usklađenosti sa farmakoterapijskim uputstvima i ekonomskih aspekta trenutne prakse propisivanja. Metode. Podaci o prometu i potrošnji antihipertenzivnih lekova propisanih kod vanbolničkih pacijenata sa dijagnozom esencijalne arterijske hipertenzije u šestomesečnom periodu prikupljeni su u državnim apotekama u Novom Sadu. Lekovi su klasifikovani prema anatomsko-terapijsko-hemijskoj klasifikaciji lekova i izračunate definisane dnevne doze (DID) na hiljadu stanovnika na dan. Rezultati. Ukupna potrošnja antihipertenzivnih lekova izdatih na recept u periodu od šest meseci u Novom Sadu bila je 283,48 DID. Najčešće korištena grupa lekova bili su inhibitori angiotenzin konvertujućeg enzima (ACEi), koji su propisivani tri puta češće od kalcijumskih antagonista i pet puta više od beta blokatora. Iako uputstva za lečenje hipertenzije navode da su svi ACEi jednako efikasni, primećena je upotreba skupljih ACEi. Upotreba diuretika i antagonista receptora angiotenzina bila je niska u posmatranom periodu. Farmakoterapijska uputstva naglašavaju prednost i efikasnost diuretika u lečenju hipertenzije kod starijih osoba, ali njihova potrošnja bila je neopravdano niska, uprkos činjenici da je preko 70% svih antihipertenzivnih lekova u Novom Sadu propisana pacijentima starijim od 60 godina. Zaključak. Ovo ispitivanje pokazalo je velike razlike u propisivanju različitih grupa antihipertenzivnih lekova. Nedovoljno korišćenje tiazidnih diuretika, lekova sa najboljim odnosom koristi i troškova i upotreba skupih ACE inhibitora je neopravdana. Postoji mogućnost za značajne uštede sa racionalnijom upotrebom ACEi, po uzoru na skandinavske zemlje.
Ključne reči
||antihipertenzivi
serbia||
||srbija
cost-benefit analysis||
||troškovi-korist
analiza
economics
pharmaceutical||
||farmakoekonomika
drug utilization review||
||lekovi
korišćenje
izveštaji.
Reference
Institute of Public Health of Serbia. Health statistical yearbook of Republic of Serbia, 2012. 2012. Available from: http://www.batut.org.rs/download/publikacije/pub2011.pdf
Čatić-Begović B. Outpatient antihypertensive drug utilization in Canton Sarajevo during five years period, and adherence to treatment guidelines assessment. Bosn J Basic Med Sci 2011; 11(2): 97−102.
World Health Organization. Noncommunicable diseases country profiles 2011. Available from: http://www.who.int/nmh/publications/ncd_profiles_report.pdf
World Health Organization. WHO report on the global tobacco epidemic 2013. Available from: http://apps.who.int/iris/bitstream/10665/85380/1/9789241505871_eng.pdf
Ministry of Health of Republic of Serbia. National health survey Serbia - 2013. 2014. Available from: http://www.zdravlje.gov.rs/downloads/2014/jul2014/Jul2014IzvestajPreliminarni.pdf (Serbian)
Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension manage-ment in England: a serial cross-sectional study from 1994 to 2011. Lancet 2014; 383(9932): 1912−9.
Lakić D, Tasić L, Kos M. Economic burden of cardiovascular diseases in Serbia. Vojnosanit Pregl 2014; 71(2): 137−43.
Ivanova A, Lakic D, Andric V, Petrova G. Cost of outpatient hypertension pharmacotherapy: comparative study between Bulgaria and Serbia. Pharm Pract 2009; 7(2): 108−12.
Kahan NR, Chinitz DP, Blackman S, Waitman D, Vardy DA. Modifying prescribing behaviour of angiotensin receptor blockers by selectively rescinding managerial prior authoriza-tion requirements for losartan. Brit J C Pharmaco 2011; 72(6): 997−1001.
Grujić V, Dragnić N, Kvrgić S, Sušnjević S, Grujić J, Travar S. Epi-demiology of hypertension in Serbia: results of a National Sur-vey. J Epidemiol 2012; 22(3): 261−6.
World Health Organization Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system. 2012. Availa-ble from: http://www.whocc.no/atcddd
Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Aberg H, et al. Drug utilization 90% - a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 1998; 54(2): 113−8.
Serbian professional committee for preparation and implementation of guidelines for good clinical practice for the diagnosis and treatment of arterial hypotension. Belgrade: (Agency for Acreditation of Health Care Institutions in Serbia) 2011. (Serbian)
Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Ger-mano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462−536.
National Institute for Health and Clinical Excellence, NICE. Clinical guideline 127- Hypertension Clinical management of primary hypertension in adults. 2011. Available from: http://www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf
Perić D, Milijašević D, Tomić N, Knežević A, Bukumirović N, Milijašević B. Use of ACE-Inhibitors in Serbia in 2009 and 2010. Hosp Pharmacol 2014; 1(3): 122−9.
Kažić T, Ostojić M. Cardiovascular drugs: Handbook for thera-py. Beograd: Integra; 2011. (Serbian)
Republic Fund for Health Insurance Serbia. List A - List of prescrip-tion drugs Issued at the expense of compulsory health insur-ance. 2012. Available from: http://www.rfzo.rs/download/04022013_Lista%20A.pdf
Republic Fund for Health Insurance Serbia. List A1 - List of pre-scription drugs with therapeutic parallel in List A. 2012. Avail-able from: http://www.rzzo.rs/download/lista_A1.pdf
Barron J, Wahl P, Fisher M, Plauschinat C. Effect of prescription copayments on adherence and treatment failure with oral anti-diabetic medications. Pharm Therap 2008; 33(9): 532−53.
Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer. J Clin Oncol 2011; 29(18): 2534−42.
Gibson TB, Mark TL, Mcguigan KA, Axelsen K, Wang S. The ef-fects of prescription drug copayments on statin adherence. Am J Manag C 2006; 12(9): 509−17.
Heagerty A. Optimizing hypertension management in clinical practice. J Hum Hypertens 2006; 20(11): 841−9.
Norwegian Institute for Public Health. Drug Consumption in Nor-way 2004–2008. 2014. Available from: http://www.legemiddelforbruk.no/english
National Agency for Medicines, Finland. Drug consumption statis-tics. 2014. Available from: http://raportit.nam.fi/raportit/kulutus/laakekulutus_e.pdf
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Com-mittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560−72.
Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. Cardiovasc Pharmacol Ther 2014; 19(1): 5−13.
Veličković-Radovanović RM, Janković SM, Avramović MŽ, Kostić S. The use of cardiovascular drugs in Niš region of Serbia. Facta Univ Med Biol 2006; 13(2): 94−7.
Sakač D, Sabo A, Jakovljević V, Stanulović M, Sakač V. Drug uti-lization in the therapy of cardiovascular diseases at the teritory of Novi Sad. Pharm Iugoslav 1995; 33(3−4): 66−8.
Stimac D, Culig J, Vukusić I, Sostar Z, Tomić S, Bucalić M. Outpa-tient utilization patterns of the six main ATC drug groups in Republic of Croatia, city of Zagreb, and Croatia counties in 2004. Coll Antropol 2009; 33(4): 1197−204.
Stolk P, van Wijk BL, Leufkens HG, Heerdink ER. Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice. J Hum Hypertens 2006; 20(12): 917−22.
Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nu-trition Examination Survey, 2001 to 2010. Circulation 2012; 126(17): 2105−14.
Radonjic V. Trade and consumption of the medicinal products – annual report 2012 Belgrade: Medicines and Medical Devices Agency of Serbia; 2013. (Serbian)
Sabo A, Tomić Z, Stilinović N, Milijašević B, Mikov M, Vukmirović S, et al. Consumption of serum lipid-reducing drugs in Serbia compared with Scandinavian countries: a population-based study, 2004-2008. Pharmacoepidemiol Drug Saf 2010; 20(1): 45−9.